Clinical Trial Update: Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose [Phase 4]

View source ↗

Summary

Phase 4 clinical trial exploring differential gene expression in heart failure patients with iron deficiency treated with ferric carboxymaltose; study terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: University of Zurich | Conditions: Heart Failure | Phase 4 | Status: TERMINATED